Mandate

Vinge advises Vicore Pharma in connection with a directed share issue

December 04, 2018 Capital Markets and Public M&A

The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs. 

The share issue is directed to a number of selected Swedish and international long-term institutional investors and sector specialist funds, on the basis of a book building procedure conducted by DNB Markets, goetzpartners securities and Zonda Partners.

Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The company’s shares are admitted to trading on Nasdaq First North. 

Vinge’s team has consisted of Jesper Schönbeck, Johan Winnerblad, Nils Fredrik Dehlin, Amanda Knutsson and Emelie Svanberg.

Related

Vinge has advised Alder on the establishment of Alder III

Vinge has advised Alder on the establishment of Alder's third and largest fund to date, Alder III.
May 27, 2024

Vinge has advised Triton in connection with sale of shares in Ambea AB (publ)

In total, 7.6 million shares were placed at a price of SEK 64 per share, corresponding to a total value of approximately SEK 489 million.
May 27, 2024